High-Dose Chemotherapy with Autotransplantation in AL Amyloidosis: A Flawed Meta-analysis  by Mehta, Jayesh et al.
138 Biol Blood Marrow Transplant 16:132-133, 2009Letters to the Editor4Department of Medicine, University of North Carolina at Chapel
Hill, Chapel Hill, North Carolina
E-mail address: wwood@unch.unc.edu
Biol Blood Marrow Transplant 16: 135-138 (2010)
 2010 American Society for Blood and Marrow Transplantation
doi:10.1016/j.bbmt.2009.06.012High-Dose Chemotherapy with
Autotransplantation in AL
Amyloidosis: A Flawed
Meta-analysis
The conclusions of the meta-analysis by Mhaskar
et al. [1] evaluating high-dose chemotherapy with
autotransplantation in immunoglobulin light chain
amyloidosis are compromised by the omission of
a key publication [2] and flawed analytical techniques.
The meta-analysis included 1 prospective randomized
study of 100 patients and 2 nonrandomized studies
containing a total of 49 patients. The pooled results
of these 3 studies showed superior overall survival
(OS) with conventional chemotherapy (CC) compared
to autologous hematopoietic stem cell transplantation
(AHSCT) (hazard ratio 1.79; P5 .018).
The meta-analysis excluded a study that compared
63 consecutive amyloidosis patients receiving high-
dose chemotherapy to 63 matched controls who
received conventional-intensity treatment [2]. The
groups were comparable in terms of age, left ventricu-
lar ejection fraction, peripheral nerve involvement,0.0
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Figure 1. A hypothetical scenario showing the survival of 3 different
populations of patients. There are 20 patients in each arm and 7 (35%)
have died in each arm.interventricular septal wall thickness, kidney function,
and bone marrow (BM) plasmacytosis; factors known
to influence OS. The 1-, 2-, and 4-year OS rates
from diagnosis were 89% and 71%, 81% and 55%,
and 71% and 41%, respectively, favoring AHSCT
(P \ .001). The 1-, 2-, and 4-year OS rates from
date of transplantation (cases) or initiation of therapy
(controls) were 82% and 68%, 81% and 53%, and
70% and 40% favoring AHSCT (P \ .001). These
findings remained unchanged when 7 patients receiv-
ing nonstandard treatment in the conventional-
intensity cohort were excluded. The outcome of
unmatched historic patients was even worse, confirm-
ing previous observations from the Mayo Clinic that
eligibility for AHSCT (the control group) improved
outcome [3]. However, the magnitude of the differ-
ence in outcomes between the control and AHSCT
groups provided strong suggestive evidence of the
benefit of AHSCT in appropriately selected patients
with amyloidosis [4].
The size and outcome of the Mayo study [2], had it
been included, would have changed the findings of the
meta-analysis completely, very likely showing benefit
of AHSCT over CC in amyloidosis. It would certainly
have undermined the current conclusion of the meta-
analysis—that outcome of AHSCT is inferior to CC.
The exclusion of the Mayo study on the grounds
that it was retrospective is not justifiable because
a number of the other single-arm AHSCT studies
included in the meta-analysis are not prospective stud-
ies. The authors must clarify whether the exclusion
was deliberate. A deliberate exclusion should have
been accompanied by a substantial discussion in the
meta-analysis on the totally contradictory findings of
the 2 studies. If the Mayo study was overlooked by
the authors, it suggests inadequate methodology and
quality control.
There are other serious methodologic and analyt-
ical errors in the manuscript.
Figure 3 in the paper apparently shows a forest
plot for the proportion of deaths with CC and
AHSCT. The plot, in fact, shows the combined
proportion of survivors in 7 of the 10 single-arm
AHSCT studies included in the analysis. Depiction
of a time-dependent event such as survival in this
manner is misleading and statistically inappropriate
because it ignores the time to event and the variable
duration of follow-up time in survivors. Figure 1 illus-
trates why the analytical technique chosen by the
authors to depict survival is incorrect. In this hypothet-
ical scenario, each of the 3 survival curves represents
20 patients, 7 of whom have died at the time of analysis.
Despite the dramatic outcome differences between the
groups, the technique employed by the authors would
simply show the proportion of deaths in each arm as
0.35, suggesting equivalence of outcome. This would
not be a statistically valid conclusion in a meta-analysis
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The meta-analysis does not clarify how patient
subpopulations were analyzed in the Gono study [5].
Table 1 states that the Gono study [5] had 31 patients.
However, in this study, although 31 patients were
recruited, only 11 were eligible for AHSCT based on
prespecified criteria. Of these 11, 7 received vincris-
tine, adriamycin, and dexamethasone (VAD) induction
followed by AHSCT; the other 4 received VAD with-
out AHSCT. Of the remaining 20, only 3 were felt to
have ‘‘satisfactory general status’’ and received VAD;
the other 17 received supportive therapy. Which
patients were considered to the treatment group and
which were the controls?
The meta-analysis also misrepresents the findings
of the van Gameren article [6]. That article included
18 patients who were eligible for the study, 12 of
whom actually participated in the study [6]. VAD
was administered to all, and 11 underwent AHSCT.
The outcome of these 18 patients was better than con-
current patients who were not eligible for the study
(and received CC) as well as historic patients who
would have been eligible for the study (AHSCT) but
received CC. It is difficult to understand howMhaskar
et al. could have interpreted the findings of the van
Gameren study as favoring CC when the published ar-
ticle shows otherwise.
Although emphasizing the higher transplant-related
mortality in the randomized French study [7], the au-
thors failed to point out that several patients in the
French study were treated at centers with limited expe-
rience in the treatment of amyloidosis using transplan-
tation [8,9]. Rare diseases that are difficult to treat,
such as AL amyloidosis, should probably be treated in
highly experienced referral centers [9,10] where appro-
priate selection of patients and systems to minimize
therapy-related mortality are refined [11]. The review
also failed to cite long-term outcome data from Boston
University showing that one-quarter of patients receiv-
ing high-dose chemotherapy were alive at 10 years, and
that the 10-year survival probability was 53% for
patients attaining complete hematologic remission [12].
Regrettably, the long list of flaws in this meta-anal-
ysis undermines its accuracy and usefulness com-
pletely. The findings as they stand could result in
inappropriate decisions that compromise patient
welfare. Physicians unfamiliar with amyloidosis could
be misled into not referring patients for an assessment
of therapeutic options on the presumption that high-
dose therapy is of no benefit. Third-party payers may
also use the flawed analysis to deny reimbursement
for this procedure. This is similar to another erroneous
meta-analysis published by the same group in
myeloma [13]. A retraction of the flawed myeloma
meta-analysis has been called for [14]. On the same
lines, it is questionable if this meta-analysis should tobe allowed to remain in the literature where its invalid
findings are used to alter or affect clinical practice.ACKNOWLEDGMENTS
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Response: Re: High-Dose
Chemotherapy with
Autotransplantation in AL
Amyloidosis: A Flawed
Meta-analysis
The primary claim put forward by Dr. Mehta et al.
is that there is ‘‘reliable’’ evidence that autologous
stem cell transplantation is superior to conventional
chemotherapy. Any reasonable observer would con-
clude with the main findings of our systematic review
that there is a paucity of reliable data on the efficacy of
autologous stem cell transplantation in AL amyloid-
osis, and this is precisely the conclusion of our manu-
script [1].
Dr. Mehta’s main critique relate to omission of an
article by Dispenzieri et al. [2] from the systematic
review, and inclusion of this article would have some-
how changed the findings. Unfortunately, Mehta and
colleagues did not read the inclusion criteria of the
systematic review attentively. The study by Dispen-
zieri et al. [2] is a retrospective study as stated in the
first sentence of the Methods section. The inclusion
criteria of this systematic review [1] clearly mentions
inclusion of prospective studies only. Nevertheless,
for the sake of academic discussion, even if we in-
cluded retrospective case-controlled studies, we would
not know which of the studies published by Dispen-
zieri et al. are to be included. In 2001, Dispenzieri
et al. [3] published a study concluding that there is
no difference in outcomes between conventional
chemotherapy and autologous stem-cell transplanta-
tion. Using essentially the same population of amyloid
patients but different selection criteria for controls, in
2004, the authors reported that autologous stem cell
transplant might be superior [2]. Additionally, in
both the articles Dispenzieri et al. [2,3] called for ran-
domized-controlled trials to definitively address the
role of transplant in AL amyloidosis as the correct
methodologic approach to settle differences high-
lighted in variety of nonrandomized controlled trials.
Consequently, we are puzzled by this apparent rever-
sal of this stand, as expressed in the letter by Dr. Mehta
and colleagues.
Mehta et al. further state that, centers in France
[4] have limited experience in treating primary ALamyloidosis, and in his opinion that is the main
reason for high treatment-related mortality [4] while
claiming the superiority of the specialized centers
in treating primary systemic AL amyloidosis. The
proclaimed superiority of the specialized centers can
be equally explained by selection bias, as these centers
may treat selective group of patients (ie, good-risk
patients) as originally pointed out by Dispenizeri
et al. [3]. Therefore, if indeed, the specialized centers
have better outcomes with autologous transplanta-
tion in comparison with other centers, the onus of
proving such claim rests with physicians practicing
in such centers (eg, by undertaking an RCT to test
this hypothesis).
In another incidence of misstatement of facts, Dr.
Mehta and colleagues refer to a meta-analysis pub-
lished in the Journal of the National Cancer Institute as
‘‘erroneous’’ without referring to the author’s reply,
which highlights the lack of basic understanding of
the meta-analytic techniques [5]. Of note, the editorial
board of Journal of the National Cancer Institute exten-
sively reviewed the manuscript and reached a decision
that the meta-analysis was properly performed, and
thus we strongly believe represents important addition
to the existing knowledge on treatment of patients with
multiple myeloma [5,6].
In summary, critique of our article by Dr. Mehta
et al. [1] is compromised by poor understanding of
the hierarchy of evidence and how reliable data are
generated in clinical research. The key message our
systematic review highlights is the absence of good
methodological quality data on the efficacy of autol-
ogous transplantation in AL amyloidosis, and the ur-
gent need for adequately powered and good
methodological quality RCTs to conclusively address
the issue related to the efficacy of autologous trans-
plantation for AL amyloidosis. We cannot under-
stand how any researcher with even a minimum
understanding of the principles of evidence-based
medicine would conclude otherwise. We understand
that Mehta and colleagues do not agree with the re-
sults of our meta-analyses [1,6]. However, we hope
that in the future critiques will be based on true sci-
entific merit rather than distorted attacks using un-
reasonable language.REFERENCES
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